三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响*

doi:10.3969/j.issn.1672-5069.2022.02.006

摘要/Abstract

摘要： 目的研究三七总皂苷(PNS)对非酒精性脂肪性肝病(NAFLD)小鼠肝脏脂质沉积及一氧化氮(NO)-诱导型一氧化氮合酶(iNOS)-核因子κB(NF-κB)信号通路的影响。方法随机将40只雄性BALB/c小鼠分为对照组、模型组、三七总皂苷(PNS)干预组和辛伐他汀干预组,每组10只。采用高脂饲料持续喂养法建立NAFLD小鼠模型,然后分别给予生理盐水或PNS或辛伐他汀灌胃干预12 w。使用全自动生化仪检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、丙氨酸氨基转移(ALT)和天冬氨酸氨基转移酶(AST),采用Western Blot法检测肝组织NO-iNOS-NF-κB通路蛋白表达。结果 PNS干预组动物体质量、肝质量和内脏脂肪比分别为(31.6±1.7)g、(6.3±0.9)g和(3.4±0.5)%,显著低于模型组【分别为(36.5±2.0)g、(8.1±1.2)g和(4.3±0.8)%,P<0.05】;血清TC、TG和LDL-C水平分别为(2.5±0.8)mmol/L、(0.9±0.3)mmol/L和(1.1±0.3)mmol/L,显著低于模型组【分别为(4.5±1.6)mmol/L、(2.7±1.1)mmol/L和(2.3±0.6)mmol/L,P<0.05】,而血清HDL-C水平为(0.4±0.2)mmol/L,显著高于模型组【(0.2±0.1)mmol/L,P<0.05】;血清ALT和AST水平分别为(32.5±6.8)U/L和(41.3±6.8)U/L,显著低于模型组【分别为(65.2±8.7)U/L和(62.7±6.9)U/L,P<0.05】;PNS干预组肝组织NO、iNOS和p-NF-κB蛋白表达相对水平分别为(1.2±0.2)、(1.1±0.1)和(1.2±0.2),显著低于模型组【分别为(5.3±0.6)、(4.8±0.5)和(5.6±0.5),P<0.05】。结论三七总皂苷可能通过抑制NO/iNOS/NF-κB通路蛋白表达从而有效降低NAFLD小鼠血脂水平,改善肝组织脂质沉积。

关键词: 非酒精性脂肪性肝病, 三七总皂苷, 肝组织脂肪变, 一氧化氮-诱导型一氧化氮合酶-核因子κB信号通路, 小鼠

Abstract: Objective The aim of this experiment was to explore the effect of panax notoginsenosides (PNS) on liver steatosis and nitric oxide (NO)-induced nitrogen monoxide synthase (iNOS)-nuclear factor kappa-B (NF-κB) pathway protein expression in mice with high-fat-induced non-alcoholic fatty liver diseases(NAFLD). Methods 40 male BALB/c mice were randomly divided into normal, model, PNS-intervened and simvastatin-intervened group, with 10 mice in each group. The NAFLD model in mice was established by feeding high fat diet for 12 weeks. After the successful model completion, the mice were feed with normal saline, PNS solution or simvastatin solution for 12 weeks. Serum total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were detected. The protein expressions of NO-iNOS-NF-κB pathway in liver tissues were detected by Western bloting. Results The body mass, liver mass and visceral fat ratio in PNS-intervened group were (31.6±1.7) g, (6.3±0.9) g and (3.4±0.5)%, significantly lower than [(36.5±2.0) g, (8.1±1.2) g and (4.3±0.8)%, P<0.05] in the model group; serum TC, TG and LDL-C levels were (2.5±0.8) mmol/L, (0.9±0.3) mmol/L and (1.1±0.3) mmol/L, significantly lower than [(4.5±1.6) mmol/L, (2.7±1.1) mmol/L and (2.3±0.6) mmol/L, respectively, P<0.05], while serum HDL-C level was (0.4±0.2) mmol/L, significantly higher than (0.2±0.1) mmol/L in the model group (P<0.05); serum ALT and AST levels were (32.5±6.8)U/L and (41.3±6.8)U/L, significantly lower than [(65.2±8.7)U/L and (62.7±6.9)U/L, respectively, P<0.05] in the model group; the relative protein expressions of NO, iNOS and p-NF-κB were (1.2±0.2), (1.1±0.1) and (1.2±0.2), significantly lower than [(5.3±0.6), (4.8±0.5) and (5.6±0.5), respectively, P<0.05] in the model group. Conclusion PNS could effectively reduce blood lipids levels and alleviate liver steatosis in mice with NAFLD, which might be related to the inhibition NO/iNOS/NF-κB pathway protein expression.

Key words: Non-alcoholic fatty liver disease, Panax notoginsenosides, Liver steatosis, Nitric oxide -induced nitrogen monoxide synthase -nuclear factor kappa-B pathway, Mice

侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.

Hou Wenjing, Wu Guangming, Gai Huihui. Effect of panax notoginsenosides on liver steatosis and NO/iNOS/NF-κB pathway protein expression in mice with high-fat-induced non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(2): 174-178.

参考文献

[1] Jarvis H, Craig D, Barker R,et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med, 2020, 17(4):e1003100.
[2] Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment ofliver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(5):1264-1281.e4.
[3] Cotter TG, Rinella M. Nonalcoholicfatty liver disease 2020:The state of the disease. Gastroenterology, 2020, 158(7):1851-1864.
[4] Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholicsteatohepatitis:A review. JAMA, 2020, 323(12):1175-1183.
[5] Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017, 23(47):8263-8276.
[6] Yao H, Qiao YJ, Zhao YL, et al. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol, 2016, 22(30):6890-6905.
[7] Liu Q, Zhu L, Cheng C, et al. Naturalactive compounds from plant food and Chinese herbal medicine for nonalcoholic fatty liver disease. Curr Pharm Des, 2017, 23(34):5136-5162.
[8] Zhang Q, Li Y, Liu M, et al. Compatibility withpanax notoginseng and rehmannia glutinosa alleviates the hepatotoxicity and nephrotoxicity of tripterygium wilfordii via modulating the pharmacokinetics of triptolide. Int J Mol Sci, 2018, 19(1):305.
[9] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15(1):11-20.
[10] Qureshi K, Abrams GA. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. Clin Obes, 2016, 6(2):117-123.
[11] Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology, 2018, 68(1):349-360.
[12] Dang Y, Hao S, Zhou W,et al. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement Altern Med, 2019, 19(1):8.
[13] Sun F, Ruan J, Zhao W,et al. New dammarane-type triterpenoid saponins from panax notoginseng leaves and their nitric oxide inhibitory activities. Molecules, 2019, 25(1):139.
[14] 王艳,苏峰,李园园,等.蜂毒溶血肽改善非酒精性脂肪性肝病大鼠肝组织脂肪沉积作用及其机制研究.实用肝脏病杂志,2019,22(4):474-477.
[15] Wandrer F, Liebig S, Marhenke S,et al. TNF-receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis, 2020, 11(3):212.
[16] Cole BK, Feaver RE, Wamhoff BR,et al. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Discov, 2018, 13(2):193-205.
[17] 吴鹏波,宋琪,俞媛洁,等.姜黄素对非酒精性脂肪性肝病细胞模型保护作用以及机制研究.实用肝脏病杂志,2020,23(3):324-327.
[18] Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clin Mol Hepatol, 2015, 21(4):319-325.
[19] Yang YM, Kim SY, Seki E. Inflammation andliver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis, 2019, 39(1):26-42.
[20] Famurewa AC, Ekeleme-Egedigwe CA, David EE,et al. Zinc abrogates anticancer drug tamoxifen-induced hepatotoxicity by suppressing redox imbalance, NO/iNOS/NF-ĸB signaling, and caspase-3-dependent apoptosis in female rats. Toxicol Mech Methods, 2020, 30(2):115-123.
[21] Zhou P, Xie W, He S,et al. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis. Cells, 2019, 8(3):204.
[22] Famurewa AC, Ekeleme-Egedigwe CA, Onwe CS,et al. Ginger juice prevents cisplatin-induced oxidative stress, endocrine imbalance and NO/iNOS/NF-κB signalling via modulating testicular redox-inflammatory mechanism in rats. Andrologia, 2020,52 (10):e13786.

三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*

Effect of panax notoginsenosides on liver steatosis and NO/iNOS/NF-κB pathway protein expression in mice with high-fat-induced non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[2]	寇卜心, 柴梦音, 豆双双, 庞丽君, 陈德喜, 刘晓霓. p53凋亡刺激蛋白2基因肝脏条件性敲除小鼠的构建和鉴定^*[J]. 实用肝脏病杂志, 2022, 25(2): 170-173.
[3]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[4]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[5]	李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[6]	莫超艳, 杨有强, 钟嫄, 肖友雪. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 231-234.
[7]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.
[8]	黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 297-300.
[9]	时牛, 宋洁, 崔天庆, 云宇婷, 郭瑞芳, 吴昆. 超声介导载miR-16-5p微泡联合树突状细胞疫苗对小鼠肝癌皮下移植瘤生长的影响^*[J]. 实用肝脏病杂志, 2022, 25(1): 17-21.
[10]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.
[11]	任洁, 郝巧歆, 黄成河, 陈勋, 卢欣. 非酒精性脂肪性肝病合并T2DM患者肠道菌群结构变化研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 54-57.
[12]	沈镇扬, 王俊俊, 陆伦根, 蔡晓波. CDE饮食诱导慢性肝损伤小鼠肝组织YAP信号对肝祖细胞增殖的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 795-798.
[13]	汪娅, 罗婷婷, 李璨, 赵文静, 陆爽. 曲美他嗪对急性肝衰竭小鼠肝组织NOX2和NOX4表达的影响[J]. 实用肝脏病杂志, 2021, 24(6): 799-802.
[14]	顾雪香, 李祥玉, 单勤星. 柴胡皂苷a通过影响PPARα信号通路对非酒精性脂肪性肝病大鼠肝脂肪变的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(6): 807-810.
[15]	王子璇, 王梦雨, 李经纬, 杨蕊旭, 曾静, 潘勤, 范建高. 门冬氨酸鸟氨酸对非酒精性脂肪性肝炎合并肌少症性肥胖小鼠的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(5): 657-660.